Please assess the completion status of the following clinical trial:

Trial Title: Optimizing Antiretroviral Therapy in HIV-Infected Children and Adolescents

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~* Evidence of HIV infection confirmed by positive culture or PCR on at least two occasions, or a positive ELISA and a confirmatory Western Blot. At least one of these tests must be done in an ACTG certified laboratory which is approved to perform the assay for protocol testing~* Age 4-21 years~* Current use of HAART regimen (NRTI or/and NNRTI based) containing a PI~* HIV-RNA levels above 1,000 copies/mL (Stage II)~* vIQ\<1 for Kaletra~* Signed informed consent and, if indicated, signed informed assent or waiver of assent.~Exclusion criteria:~* Grade 3-4 DAIDS defined toxicity~* Use of cimetidine (used as the internal standard for the HPLC-MS/MS assay)~* Any active opportunistic infection~* Any of the following laboratory findings at entry: absolute neutrophil count \<750 cells/mm3; platelet count \<75,000 cells/mm3; AST \>3 times upper limit of age adjusted normal values; ALT \>3 times upper limit of age adjusted normal values; serum creatinine \>1.2mg/dL.~* Patients on dual PI regimen (except when second PI is given for boosting) at the time of enrollment

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Therapeutic Dose Adjustment (Type: None): To adjust the doses of medications to meet target therapeutic concentrations

Based on this trial design, predict the completion outcome and termination type (if applicable).